[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models

• DOI: 10.1007/s13402-020-00539-z
• Publication Date: 2020-08-06T08:04:04Z
• Authors: Ana Carolina Bapt...; Rebeka Tomasin; Liany Luna-Dulcey; Angélica Elen Gra...; Marina Araújo Naves; Ramon Handerson G...; Vinicius Duval da...; James Almada da S...; Paulo Cezar Vieira; Borhane Annabi; Márcia Regina Com...
• Keywords: Mice, Inbred BALB C; Cell Death; Catechols; Antineoplastic Agents; Apoptosis; Drug Synergism; Triple Negative Breast Neoplasms; Cell Cycle Checkpoints; Xenograft Model Antitumor Assays; 3. Good health; Inhibitory Concentration 50; 03 medical and health sciences; 0302 clinical medicine; Doxorubicin; Cell Line, Tumor; Animals; Humans; Fatty Alcohols; Neoplasm Metastasis; Tumor Stem Cell Assay; Cell Proliferation

Although doxorubicin is widely used to treat cancer, severe side effects limit its clinical use. Combination of standard chemotherapy with natural products can increase the efficacy and attenuate the side effects of current therapies. Here we studied the anticancer effects of a combined regimen comprising doxorubicin and [10]-gingerol against triple-negative breast cancer, which does not respond to hormonal or targeted therapies.Cytotoxicity was evaluated by MTT assay, cell cycle progression and apoptosis were analyzed by flow cytometry and signaling pathways were analyzed by Western blotting in human and murine triple negative breast cancer cell systems. The anticancer/antimetastatic and toxic effects of the combined regimen was evaluated using syngeneic and xenograft orthotopic models.The combination of doxorubicin and [10]-gingerol significantly increased the number of apoptotic cells, compared to each compound alone. In 4T1Br4 cells, the combined regimen was the only condition able to increase the levels of active caspase 3 and γH2AX and to decrease the level of Cdk-6 cyclin. In vivo, doxorubicin (3 mg/Kg, D3) and [10]-gingerol (10 mg/Kg, G10) resulted in a significant reduction in the volume of primary tumors and a decrease in the number of circulating tumor cells (CTCs). Interestingly, only the combined regimen led to decreased tumor burdens to distant organs (i.e., metastasis) and reduced chemotherapy-induced weight loss and hepatotoxicity in tumor-bearing animals. Likewise, in a xenograft model, only the combined regimen was effective in significantly reducing the primary tumor volume and the prevalence of CTCs.Our data indicate that [10]-gingerol has potential to be used as a neoadjuvant or in combined therapy with doxorubicin, to improve its anticancer activity.